** U.S. shares of Israel-based biotech co  APOP.O  rise
75.53% to $4.16 premarket
    ** Co reports positive data from bone marrow transplant
study
    ** Co's technology platform, ApoGraft, selects stem cells
for safe and efficient cell therapies by retaining most of the
stem cells but neutralizing harmful mature cells         
    ** Co says its pre-clinical study using ApoGraft for bone
marrow transplantation demonstrates robust engraftment - when
transplanted cells grow and make healthy blood cells
    ** There have been no safety or tolerability concerns so far
- co
    ** Data submitted to U.S. FDA during Investigational New
Drug approval process - APOP
    ** Up to last close, shares up 6.77% YTD 

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))